EFFICIENCY OF THE COMBINED ANTIVIRAL THERAPY OF THE CHRONIC HEPATITIS FROM THE GENOTYPE 1 AT LOW VIRUS LOADING PREPARATIONS ALTEVIR AND RIBAVIRIN
Genotype HCV consider as the most important the predictor proof virology answer. Taking into account high speed of a reproduction and unique genetic heterogeneity HCV advantages of a daily mode of introduction an IFN-alpha express. Fast decrease in level viremia is shown at daily use an IFN-alpha. Introduction IFN-alfa2b - altevir а in a dose of 3 million МЕ daily the first 24 weeks with the subsequent transition to a mode every other day, 24 weeks, in comparison with a starting mode of 3 million МЕ every other day, 48 weeks, increases percent of proof biochemical and virology remission.